Home › NCT04895956

Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Signed informed consent from the patient exclusively and not a legal representative
* Clinically diagnosed with De Quervain's
* VAS score of at least 40mm pre-injection
* Life expectancy greater than 1 year

Exclusion Criteria:

* Having previously undergone steroid injection in the treatment of De Quervain's
* Having previously undergone surgery for De Quervain's in the affected wrist
* Having previously undergone steroid injection and failed in the treatment of trigger finger
* Allergies to lidocaine or dexamethasone
* Underlying serious medical conditions that would place the patient at risk
* Past history of hypothyroidism or rheumatoid arthritis
* Pregnant women
* Prisoners

About the study

The aim of the study is to determine whether or not extra-sheath steroid injections are inferior to intra-sheath steroid injections in the treatment of DeQuervain's Tenosynovitis.

Patients will be randomized to either the intra-sheath group or the extra-sheath group and their pre-injection level of pain will be assessed using the visual analog scale. Appropriate injections will then be administered by 1 of 3 UC Davis hand surgeons. Six weeks post injection the patients will be reassessed using the visual analog scale and their score at 6 weeks will be compared to their pre-injection score.

What is being tested

• Intra-sheath injection (procedure)
• Extra-sheath injection (procedure)
• Ultrasound (device)

Sponsor: University of California, Davis · Participants: 80 · Started: Jan 24, 2022

Contact the study team

• Julia Martin, MS · Phone: 916-7348175
• Christopher O Bayne, MD · Phone: (916) 734-2700

Official record on ClinicalTrials.gov — NCT04895956

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.